Rearrangements of the MLL gene occur in both acute lymphoblastic and acute myeloid leukemias (ALL, AML). This study addressed the global gene expression pattern of these two leukemia subtypes with respect to common deregulated pathways and lineage-associated differences. We analyzed 73 t(11q23)/MLL leukemias in comparison to 290 other acute leukemias and demonstrate that 11q23 leukemias combined are characterized by a common specific gene expression signature. Additionally, in unsupervised and supervised data analysis algorithms, ALL and AML cases with t(11q23) segregate according to the lineage they are derived from, that is, myeloid or lymphoid, respectively. This segregation can be explained by a highly differing transcriptional program. Through the use of novel biological network analyses, essential regulators of early B cell development, PAX5 and EBF, were shown to be associated with a clear B-lineage commitment in lymphoblastic t(11q23)/MLL leukemias. Also, the influence of the different MLL translocation partners on the transcriptional program was directly assessed. Interestingly, gene expression profiling did not reveal a clear distinct pattern associated with one of the analyzed partner genes. Taken together, the identified molecular expression pattern of MLL fusion gene samples and biological networks revealed new insights into the aberrant transcriptional program in 11q23/MLL leukemias. Leukemia (2005) 19, 953-964.
Introduction
The MLL gene (also termed ALL-1, HRX, and TRX1) located at chromosome band 11q23 is a recurrent target of chromosomal translocations in acute leukemias, particularly prevalent in infant leukemias and treatment-related secondary leukemias, and associated with dismal prognosis. [1] [2] [3] Reciprocal translocations associated with the MLL gene result in in-frame fusion transcripts with various partner genes from at least 50 distinct gene loci. 4 In addition, a partial tandem duplication of the MLL gene has been reported. 5 The class of oncogenic MLL fusion proteins consists of the N-terminal portion of the MLL protein fused to C-terminal portions of a fusion partner. Experimental systems in which MLL fusion proteins were generated to induce leukemia in mice demonstrated that this fusion to a C-terminal partner is necessary for immortalization. Two critical regions within MLL were identified: a region with three AT hook DNA-binding motifs and the DNA methyltransferase homology region. 6 The MLL fusion partners act via dominant gain of function and seem to play a role in two main functional categories, namely signaling molecules that normally localize to the cytoplasm/cell junctions or nuclear factors implicated in regulatory processes of transcription. 7 With respect to the oncogenic activation of MLL in leukemia So and Cleary proposed two mechanisms. One subset of fusion partners already displays the required transcriptional activation potential required for leukemogenesis. The other subset acts via their homodimerization or oligodimerization domains and therefore can lead in a dimerization-dependent pathway to deregulated transcription. 8 Interestingly, distinct MLL fusion partners suggest a possible role in the tropism of the leukemia. Certain partner proteins not only convert MLL to an oncogenic fusion protein but also direct the lineage susceptibility for transformation. MLL-AF4 expressing leukemias are mainly diagnosed as pro B ALL (acute lymphoblastic leukemia), whereas, for example, fusion partners AF9, AF6, or AF10 are common in myelomonocytic or monoblastic AML (acute myeloid leukemia) subtypes. 9 Microarrays simultaneously assess the abundance of thousands of mRNA transcripts. 10 During the past few years powerful algorithms have been developed and adapted to mine microarray data. 11 More recently also applications to interprete gene expression signatures in terms of pathways and networks have evolved. In this study, from a series of 363 acute leukemia patient samples hybridized to a set of high-density microarrays representing a near complete human genome, analyses were performed to (i) identify t(11q23)/MLL gene signatures compared to numerous specific subtypes of acute leukemias, (ii) discriminate t(11q23)/MLL-positive AML from t(11q23)/MLL ALL samples, (iii) investigate signatures correlated with MLL-AF9 and other MLL partner genes, and (iv) decipher common biological networks. Specifically we addressed the question how the differing MLL partner genes influence the global gene expression signature and whether pathways could be identified to explain the molecular determination of MLL leukemias occurring in both the myeloid and lymphoid lineages.
Materials and methods

Patient samples
This study included bone marrow samples from 363 adult acute leukemia patients at diagnosis representing distinct precursor B-ALL subtypes t(11q23)/MLL, t (8;14) , t(9;22) and precursor T-ALL as well as AML subtypes with t(11q23)/MLL, t(8;21), t (15;17) , inv (16) , or complex aberrant karyotype (Supplementary Table 1 ). In AML with t(11q23)/MLL, 15 out of 48 cases were therapy-related. Seven out of these 15 cases followed exposure to topoisomerase II inhibitors. All samples were sent between December 1998 and February 2004 for reference diagnostics to our laboratory and were registered in our leukemia database.
Prior to therapy, all patients gave their informed consent for participation in the current evaluation after having been advised about the purpose and investigational nature of the study as well as of potential risks. The study design adhered to the declaration of Helsinki and was approved by the ethics committees of the participating institutions prior to its initiation. The diagnosis was performed by an individual combination of cytomorphology, cytogenetics, fluorescence in situ hybridization (FISH), multiparameter-immunophenotyping, and molecular genetics. In particular, a thorough characterization of the t(11q23)/MLL samples was warranted. Cytogenetic characterization, FISH on interphase nuclei and/or metaphases, and MLL fusion transcripts PCR detection was performed as previously described. 3 
Gene expression profiling and statistical methods
Microarray analyses were performed as previously described utilizing the GeneChip System (Affymetrix, Santa Clara, CA, USA) and the HG-U133 microarray set. [13] [14] [15] [16] Details on the procedure are provided in the online section.
For supervised statistical analyses, samples were accordingly grouped and for each disease entity differential genes were calculated by means of t-test-statistic (two-sample t-test, unequal variances). 17 We applied the software package R version 1.7.1 (http://www.r-project.org/). To address the multiple testing problem, false discovery rates (FDR) of genes were calculated according to Storey and Tibshirani. 18 The class prediction was performed using support vector machines (SVM), 19 because there is evidence that SVM-based prediction slightly outperforms other classification techniques. 20 ,21 SVM models were built with libsvm (http:// www.csie.ntu.edu.tw/~cjlin/libsvm/). For further details, see Supplementary Information.
As an additional method to extract differentially expressed genes, the SAM software program (MS Excel application) was used. 22 Microarray signal intensities were transformed as described above and subsequently imputed into the software. A stringent cutoff for significance (tuning parameter delta) for o1 false positive-rated gene was chosen.
The resulting gene expression data was visualized using hierarchical cluster and principal component analysis (GeneMaths XT, Applied Maths, Belgium). For visualization of unsupervised data analyses, a variation filter was applied. This filter aimed at removing probe sets that demonstrated minimal variation across the complete data set. Practically, for each gene the standard variance was calculated across all samples. Then the data matrix was sorted according to the standard variances, and probes, demonstrating a low variance were excluded from the subsequent analysis.
Biological networks analysis
Biological networks have been generated through the use of Ingenuity Pathways Analysis (August 2004 release version), a web-delivered application that generates networks using differentially expressed genes from microarray analyses. The networks address two different questions: (i) discrimination of t(11q23)/ MLL from other genetically defined acute leukemia subtypes, and (ii) discrimination of ALL with t(11q23)/MLL from AML with t(11q23)/MLL. In both analyses, a data set containing gene identifiers in probe set format and their corresponding fold change characteristics was uploaded as a tab-delimited text file into the Ingenuity pathway database. The networks are displayed graphically as nodes (genes) and edges (the biological relationships between the nodes). Nodes are further displayed using various shapes that represent the functional class of the gene product. Edges are displayed with various labels that describe the nature of the relationship between the nodes. The length of an edge reflects the evidence supporting that node-to-node relationship, in that edges supported by more articles from the literature are shorter. A detailed description of the procedure and various legends are available online in the Supplementary section.
Results
Distinct gene expression signatures in t(11q23)/MLL leukemias
We first compared the expression profiles of all 73 adult t(11q23)/MLL-positive samples (n ¼ 25 ALL and n ¼ 48 AML with t(11q23)/MLL) to 204 adult myeloid and 86 lymphoblastic leukemia samples with other defined genetic aberrations). In a supervised data analysis approach, a robust set of differentially expressed genes was identified which accurately stratified the samples according to their underlying cytogenetic and immunophenotypic characteristics, that is, myeloid subclasses, precursor B-lineage, or precursor T-lineage ALL. In detail, for lymphoblastic leukemias, t(11q23)/MLL samples (n ¼ 25) were accurately separated from precursor B-ALL cases with t(9;22) (n ¼ 42), t(8;14) (n ¼ 12), and precursor T-ALL (n ¼ 32). Figure 1a (Figure 1b) . The online section contains the top 50 genes with higher expression or lower expression, respectively, in AML with t(11q23)/MLL, as well as data from an unsupervised analysis (Supplementary Table 3 , Supplementary Figure 7) .
Thus, in both types of acute leukemias, t(11q23)/MLL-positive samples are clearly distinct from other subtypes of same cell lineage, that is, myeloid or lymphoblastic. They have a characteristic underlying expression signature compared to other distinct acute leukemia subclasses.
Subsequently, all samples were included into one comprehensive analysis. A supervised data analysis algorithm was applied to identify genes that separate each of the nine subtypes from the remaining classes. As shown in Figure 2 , the nine distinct acute leukemia subtypes can accordingly be separated. The hierarchical clustering algorithm identified common expression signatures and orders the patient samples accurately by similarities. Interestingly, t(11q23)/MLL-positive samples are not found to cluster together but rather according to the lineage they are derived from, that is, a lymphoblastic t(11q23)/MLL cluster and a myeloid t(11q23)/MLL cluster can be observed. In the top dendrogram, ALL samples with t(11q23)/MLL are grouped next to ALL with t(9;22) and t (8;14) , and AML with t(11q23)/MLL are grouped next to AML with t(15;17) or AML with t(8;21) cases. This finding can also be observed in unsupervised analyses using hierarchical clustering (Supplementary Figure 8) and PCA (Supplementary Figure 9) .
Common MLL target genes
In order to identify common MLL target genes, both types of t(11q23)/MLL leukemias were grouped together and were compared to the various types of precursor B-and Tlineage ALLs as well as to other cytogenetically defined AML subtypes. In doing so, a set of differentially expressed genes specifically associated with t(11q23)/MLL leukemias was specified. Relationships between these genes were further examined using a network analysis application. As given in Figure 3 , HOXA9 as well as MEIS1 show up as genes with higher expression in both t(11q23)/MLL leukemias. Other genes with higher expression in this network included NICAL and chromatin remodeling actor RUNX2. Downregulated genes included, for example, TNF-receptor superfamily members TNFRSF10A and TNFRSF10D, or MADH1, functioning downstream of TGF-beta receptor serine/threonine kinases. Three additional networks are available as online Supplementary material. They visualize networks containing other genes with known relationship with t(11q23)/MLL leukemias, for example, HOXA cluster genes (HOXA5, HOXA10), as well as the Hox coregulator PBX3, or the tyrosine kinase FLT3. Other target genes with higher expression in t(11q23)/MLL leukemias included HIP1, so far associated with prostate cancer progression, proto-oncogene FRAT1, TAF1B, playing a role in the tumorigenesis of colorectal carcinomas, and ZFHX1B, a transcriptional corepressor. More detailed information on all focus and nonfocus genes, as well as gene expression signal intensities for all genes included in the four networks is available in the online section. The top 50 genes with higher expression or lower expression, respectively, in both leukemias with t(11q23)/ MLL combined are given in the online section (Supplementary Table 4 ). Biological network distinguishing t(11q23)/MLL leukemias from other acute leukemia subtypes. The network is graphically displayed with genes/gene products as nodes and the biological relationships between the nodes as edges. The intensity of the node color indicates the degree of differential gene expression. Green intensities correspond to a lower expression (downregulated) in t(11q23)/MLL cases compared to AML subtypes (inv(16), t(8;21), t(15;17), complex karyotypes) or ALL subtypes (t(9;22), t(8;14), T-ALL), respectively. Red intensities correspond to a higher expression in t(11q23)/MLL cases (upregulated), respectively. Nodes are displayed using various shapes that represent the functional class of the gene product (for detailed legend, see online section). Edges are displayed with labels that describe the nature of the relationship between the nodes (B for binding, E for expression, A for activation/deactivation). Note: Focus genes were included in the original text format file derived from the list of differentially expressed genes (for details, see Supplementary document). Nonfocus genes were derived from queries for interactions between focus genes and all other gene objects stored in the Ingenuity knowledge data base. Gene expression raw data is available online as Supplementary Data Set 2.
Gene expression profiling in t(11q23)/MLL acute leukemias
A Kohlmann et al leukemias are characterized by an MLL gene rearrangement, an unsupervised data analysis approach clearly separates the samples according to their hematopoietic lineage, that is, myeloid or lymphoblastic origin. Moreover, given the dendrogram from the unsupervised hierarchical cluster analysis, no clear subclustering of cases with identical MLL partner genes can be observed (Figure 4b ). In ALL with t(11q23)/MLL, the MLL-ENL cases intercalate with the MLL-AF4 samples. In AML with t(11q23)/MLL, no obvious structure, neither according to FAB criteria nor to the MLL partner genes can be observed. The MLL-AF6, MLL-AF10, MLL-ELL, as well as rare cases (MLL-p300, MLL-AF17, MLL-SMAP1, MLL-X) are intercalated between the MLL-AF9 samples. Thus, two independent unsupervised algorithms consistently separate MLL gene rearranged leukemias into ALL and AML subgroups but not with respect to the partner genes.
Supervised analysis to discriminate t(11q23)/MLL translocation positive leukemias
We next directly compared expression signatures of ALL with t(11q23)/MLL to AML with t(11q23)/MLL in a supervised algorithm. Among the differentially expressed genes, upregulated candidates in lymphoblastic leukemias demonstrated a dominant pattern according to B-lineage commitment. PAX5, the B-cell-lineage-specific activator was designated as one of the top-ranked differentially expressed genes. In line with this finding, PAX5 target genes BLK and CD19 could also be confirmed upregulated in ALL with t(11q23)/MLL by microarray analysis. An upregulated expression of IGHM (encoding the IgM heavy chain), VPREB1 (surrogate light-chain, important for forming the pre-B-cell receptor), and CD22 or CD79A further elucidates the B-lineage commitment of ALL with t(11q23)/MLL. In addition, the list of differentially expressed genes was also imputed into a pathway analysis application. Various networks of functionally related genes were obtained. In Figure 5 , a biological network is represented. Seven additional networks are available as online Supplementary material. In this network, LEF1, a transcriptional regulator is connected to PAX5 and its target CD79A, which is included in the B-cell antigen receptor. These genes, as well as the transcriptional regulators MEF2A and TCF3 demonstrated a higher expression in ALL with t(11q23)/ MLL profiles compared to AML with t(11q23)/MLL cases. In the Supplementary networks further interesting differentially expressed genes with higher expression in t(11q23)/MLL-positive ALL include BCL11A, also involved in lymphoid malignancies, transcription regulator ETS2, chromatin-binding proteins CBX2 and CBX4, and early B-cell factor EBF, which can restrict lymphopoiesis to the B-cell lineage and works in concert with PAX5 to activate genes required for B-cell differentiation. 
AML with t(11q23) ALL with t(11q23)
Unsupervised analysis of adult ALL and AML t(11q23)/ MLL samples. (a) Unsupervised analysis using a selection of 5000 genes that showed the largest variance across all samples. In the threedimensional PCA plot, data points with similar characteristics will cluster together. Each patient's expression pattern is represented by a single color- 
Reversely, genes with higher expression in t(11q23)/MLLpositive AML included the transcriptional activator CEBPB, protein tyrosine kinase KIT, MADH2, a transcription factorbinding protein, and MITF, a transcriptional regulator ( Figure 5 ). As illustrated in the Supplementary networks, a myeloid commitment through higher expression in AML with t(11q23)/ MLL could be demonstrated by differential expression of CEBPA (CCAAT/enhancer-binding protein-alpha), a transcription factor required for differentiation of myeloid progenitors, as well as SPI1 (PU.1), a critical player in myeloid development, or granulocyte/macrophage colony-stimulating factor (GM-CSFR) and granulocyte colony-stimulating factor (G-CSFR) genes. Other candidates with significantly higher expression in t(11q23)/MLL positive AML are FES, a tyrosine kinase oncogene, MNDA, encoding the myeloid cell nuclear differentiation antigen, or CITED4, a CBP/p300-interacting transcriptional transactivator. Also, a different repertoire of expression of suppressors of cytokine signaling (SOCS) family members as well as members of the tumor necrosis factor superfamily could be observed.
More detailed information on all focus and nonfocus genes, as well as gene expression signal intensities for all genes included in the eight networks is given in the online section.
Influence of MLL translocation partners on the gene expression signatures
First, within the cohort of AML and t(11q23)/MLL samples, the group of t(9;11)-positive cases (n ¼ 23) was compared to 
Figure 5
Differentially expressed genes between ALL with t(11q23)/MLL and AML with t(11q23)/MLL. A biological network is displayed graphically. Details for the legend can be obtained in Figure 3 or in the Supplementary document. Green intensities correspond to a lower expression in ALL with t(11q23)/MLL cases compared to AML with t(11q23)/MLL samples (downregulated). Red intensities correspond to a higher expression in ALL with t(11q23)/MLL cases compared to AML with t(11q23)/MLL samples (upregulated). Gene expression raw data is available online as Supplementary Data Set 3.
Gene expression profiling in t(11q23)/MLL acute leukemias
A Kohlmann et al non-t(9;11)-positive samples (n ¼ 25). Neither supervised nor unsupervised analyses revealed a specific expression signature associated with the MLL translocation partner AF9. In Figure 6 , SAM plots demonstrate that compared to the previous analysis of ALL with t(11q23)/MLL versus AML with t(11q23)/MLL no significantly differentially expressed genes clearly correlate to the MLL-AF9 translocation (left plot). The q-values of the top differentially expressed genes ranged between 0.75 and 0.82, that is, calling this set of genes significant would result in an FDR of 475%. For comparison, a very high number of differentially expressed genes can be identified when comparing ALL with t(11q23)/MLL versus AML with t(11q23)/MLL (right plot). Furthermore, as demonstrated in Figure 7 , the unsupervised data analysis approach including all t(11q23)/MLL samples also did not reveal any specific patterns associated with distinct MLL partner genes. It is interesting to note that MLL-ENL samples, included both in the AML and ALL patient cohorts are separated. Four ALL cases with MLL-ENL intercalate with the MLL-AF4 samples, two AML with MLL-ENL samples are distributed between the various cases in the AML cluster. Additionally, in the AML cluster, no clear distinction between de novo cases and t-AML cases following exposure to topoisomerase II inhibitors can be observed (details are given in the online Supplementary Document).
A more detailed analysis then aimed at mining the data supervised for differential gene expression between various MLL partner genes. Here, six groups of MLL patient samples were included: AML cases with t(9;11)/MLL-AF9 (n ¼ 23), t(6;11)/ MLL-AF6 (n ¼ 7), t(10;11)/MLL-AF10 (n ¼ 4), and t(11;19)/MLL-ELL cases (n ¼ 3); as well as ALL samples with t(4;11)/MLL-AF4 (n ¼ 21) and t(11;19)/MLL-ENL (n ¼ 4). In this data set, no statistically significant expression signatures were found to be specifically correlated with one of the distinct partner genes. Predicting the respective partner gene based on differential gene expression signatures was approached using Support Vector Machines (SVM). Taking the six different subgroups into account, the complete data set was randomly separated into a training cohort and an independent test cohort. Then differentially expressed genes were identified in the training set, calculated by means of t-test-statistic, and an SVM model was built based on the top 100 genes that demonstrate differential expression between the respective subclasses in the training set. This SVM model was used to predict samples in the test cohort. Table 1 represents a confusion matrix of MLL subgroup predictions based on their gene expression signature using a 10-fold crossvalidation approach. It can be observed that the classifier is good at predicting the MLL partner genes AF9 and AF4, the two major groups in the AML and ALL patient cohorts, respectively. Other partner genes are not accurately identified. The misclassifications mainly occur in the corresponding Unsupervised analysis of adult ALL and AML t(11q23)/ MLL samples. The unsupervised analysis is based on 5000 genes that showed the largest variance across all samples. For better visualization, the labels and coloring of the classes were added after the analysis. In the three-dimensional PCA plot, data points with similar characteristics will cluster together. Here, each patient's expression pattern is represented by a single color-coded sphere. For each sample, the MLL fusion partner gene as confirmed by FISH and/or PCR-based molecular analyses is given. MLL-X indicates samples with unknown partner genes. In order to assess the robustness of partner gene prediction, a resampling approach was applied, that is, the complete SVM classification procedure was repeated for 100 times. The training set included 2/3 of patients, the test set 1/3. Here, the test set for each of the 100 runs included 20 samples which were randomly chosen from the total patient cohort to include one MLL-AF10, two MLL-AF6, eight MLL-AF9, one MLL-ELL, seven MLL-AF4, and one MLL-ENL sample. Given the differential gene expression mainly the MLL partner genes AF9 and AF4, dominating the patient cohort, are given correct class labels by the classification algorithm ( Table 2) .
Discussion
Recent studies successfully applied microarrays to classify known hematological malignancies, as well as to discover novel subtypes and to identify genetic differences associated with distinct prognostic subgroups. [23] [24] [25] In pediatric and adult acute leukemias, distinct gene expression signatures were correlated with t(11q23)/MLL-positive cases. 14, 15, [26] [27] [28] [29] [30] [31] [32] Using both a larger cohort of patients and an up-to-date microarray design, we confirmed our data that AML subtypes carrying the specific balanced chromosomal aberrations t(8;21), t(15;17), and inv(16) demonstrate highly characteristic expression signatures. Furthermore, the present study was extended to include AML cases with MLL gene rearrangements and shows that AML with t(11q23)/MLL can also be associated with a distinct expression signature.
We also analyzed four differing adult ALL subtypes. Precursor B-ALL with t(11q23)/MLL, t(9;22), or t(8;14) and precursor T-ALL all form distinct clusters in various data analysis approaches which reflect their highly differing underlying gene expression profiles. This is in line with previous reports showing that pediatric and adult ALL with t(11q23)/MLL, t(9;22), or precursor T-ALL samples, respectively, can be separated and also predicted with high accuracies using microarray technology. 14, 28, 32 We demonstrated that in a comprehensive analysis including numerous classes of defined acute leukemia subtypes t(11q23)/MLL patient samples were distinct.
This study further aimed at identifying common targets of MLL chimeric fusion genes. In order to designate common target genes, both types of acute leukemias with MLL translocations were combined and were compared to various types of other precursor B-and T-lineage ALLs as well as to other cytogenetically defined AML subtypes. This supervised analysis resulted in a list of statistical significant differentially expressed genes irrespective of lineage. A closer examination of these genes showed that also in our data a significantly overexpressed 'Hox code' was detectable, that is, overexpression of HOX-A cluster members. 33 Other genes with higher expression in t(11q23)/MLL leukemias have also been previously reported to be implicated in MLL-related leukemogenesis, that is, MEIS1, and PBX3. 34, 35 However, here it could further be demonstrated how the t(11q23)/MLL leukemia-associated genes are related to each Table 1 MLL partner gene confusion matrix determined by 10-fold crossvalidation The matrix shows the predicted MLL fusion partner gene as determined after 100 runs of SVM-based classifications. Misclassified samples are given by bold letters. Average numbers of predictions per run are given. For example, seven MLL-AF4 samples have been predicted by the algorithm 700 times (each sample 100 times). Of the 700 predictions, the class label MLL-AF4 has been given correctly 659 times, that is, on average 6.59 per run. In nine individual predictions, an MLL-AF4 sample has been predicted as MLL-AF9, in one prediction as MLL-ELL, and in 31 predictions as MLL-ENL, respectively.
Gene expression profiling in t(11q23)/MLL acute leukemias A Kohlmann et al other in a novel constellation. As given in the respective networks consistently upregulated candidates with oncogenic potential included, for example, RUNX2, HIP1, FRAT1, TAF1B, and ZFHX1. RUNX2 normally plays a key role in osteogenesis but also a direct oncogenic role had been proposed. 36, 37 HIP1 encodes an endocytic protein with transforming properties that is involved in a cancer-causing translocation and which is overexpressed in a variety of human cancers. 38 Proto-oncogene FRAT1 represents the human homologue to mouse protooncogene Frat1, which promotes carcinogenesis through activation of the Wnt/beta-catenin/TCF signaling pathway.
39
TAF1B has been identified to play a role in the tumorigenesis of colorectal carcinomas with microsatellite instability.
40 ZFHX1 encoding Smad-interacting protein 1 (SIP1) directly represses E-cadherin gene transcription and activates cancer invasion via the upregulation of the matrix metalloproteinase gene family. 41 Consistently downregulated genes in t(11q23)/MLL leukemias included TNF-receptor superfamily members required in TRAILmediated apoptosis, TNFRSF10A and TNFRSF10D, 42 or MADH1 (SMAD1), functioning downstream of TGF-beta receptor serine/threonine kinases. 43 However, it only can be speculated whether the dysregulated expression of these genes confer any resistance to apoptotic stimuli.
The t(11q23)/MLL leukemias are generally associated with a high risk of treatment failure and therefore novel therapeutic strategies are needed to improve the outcome in patients with 11q23 abnormalities. Small molecule inhibitors of FLT3, a receptor tyrosine kinase, may prove to be beneficial. 44 In recent studies, high levels of FLT3 expression in patients with MLL rearrangements have been identified and FLT3 successfully has been validated as a therapeutic target. 26, 45 We also can observe an overexpression of FLT3 in both t(11q23)/MLL leukemias compared to other acute leukemia classes. The corresponding network including the FLT3 gene is available online (network MLL target 2).
We further demonstrated that ALL and AML cases with t(11q23)/MLL segregate according the lineage, that is, myeloid or lymphoblastic, respectively. In unsupervised data analyses the cases with MLL gene translocations did not cluster as a unique subgroup, but instead clustered according to their lineage of origin. Therefore, we propose that MLL aberrations lead to specific expression signatures but that there is a clear identification of lymphoblastic lineage commitment for ALL with t(11q23)/MLL. This has also recently been demonstrated by Ross et al 29 in a pediatric cohort of patients. We now could demonstrate that this cellular differentiation can be explained by a transcriptional program and further elucidated this through the use of biological network analysis. Among the top-ranked differentially expressed genes to discriminate ALL and AML cases with t(11q23), PAX5 was represented. PAX5 restricts the developmental options of lymphoid progenitors to the B-cell lineage by repressing the transcription of lineage-inappropriate genes and simultaneously activating the expression of B-lymphoid signaling molecules. 46 Its influence can also be followed more downstream when we focused on PAX5 target genes, also included in the list of top-ranked differential genes. It is known that, for example, BLK or CD19 are controlled by PAX5. As visualized in the respective biological networks, these and other B-lineage characteristic candidates (CD79A, VPREB1, CD22) were grouped together, all with higher expression in MLL gene rearranged ALL compared to AML samples. Interestingly, not only PAX5 but also EBF a second essential regulator of early B-cell development was higher expressed in ALL with t(11q23)/ MLL. Specific activities of these proteins include roles in chromatin remodeling and recruitment of partner proteins. 47 Taken together, a multitude of genes visualized a strong B-lineage commitment in lymphoblastic t(11q23)/MLL leukemias. Other interesting candidates with higher expression in ALL with t(11q23)/MLL for subsequent experimentation include CBX2 and CBX4, both components of the chromatin-associated polycomb complex. Polycomb group proteins assemble to form large multiprotein complexes that are thought to repress their targets by modifying chromatin structure. 48 It has been suggested that interference with CBX4 function can lead to derepression of proto-oncogene transcription and subsequently to cellular transformation. 49 With respect to AML with t(11q23)/MLL, in another network a transcriptional pattern for myeloid commitment was represented through the higher expression of key players in myeloid development, CEBPA and SPI1 (PU.1). The finding that C/EBPalpha binds and activates the endogenous PU.1 gene in myeloid cells further contributes to the specification of myeloid progenitors. 50 Also, genes encoding the receptors for GM-CSFR and G-CSFR clearly underline a completely differing transcriptional program since it has been suggested that G-CSFR signals may play a role in directing the commitment of primitive hematopoietic progenitors to the common myeloid lineage. 51 Also, the downregulation of GM-CSFR represents a critical event in producing cells with a lymphoid-restricted lineage potential. 52 Other differentially expressed genes with higher expression in t(11q23)/MLL-positive AML included, for example, FES, a tyrosine kinase oncogene, implicated in signaling downstream from hematopoietic cytokines. 53 FES may be a key component of the granulocyte differentiation machinery and contributes to lineage determination at the level of multilineage hematopoietic progenitors as well as the more committed granulo-monocytic progenitors. 54 Another gene that may be involved in myeloid differentiation is MNDA, encoding the myeloid cell nuclear differentiation antigen. 55 It is expressed exclusively in maturing myeloid cells and cell lines, and is not expressed in lymphoid cells. Recent data suggest that there is a strong correlation between MNDA expression and myeloid differentiation. 56 Here, MNDA expression further elucidates the myeloid lineage specificity in t(11q23)/MLL-positive AML. Lastly, CITED4, a CBP/p300-interacting transcriptional transactivator, is significantly higher expressed in AML with t(11q23)/MLL. 57 It may function as a coactivator for transcription factor AP-2 and possible roles for CITED4 in regulation of gene expression during development and differentiation of blood cells have been implied. 58 A major goal of this study was to directly assess the influence of the different MLL translocation partners on the transcriptional program. We performed a supervised comparison of MLL-AF9-positive samples to MLL-AF9-negative samples in AML. No statistically significant differences were found. Using SAM plots to visualize the degree of differences in their gene expression pattern we observed that within AML the MLL-AF9-positive samples were very similar compared to the MLL-AF9-negative samples. Furthermore, as demonstrated by an unsupervised data analysis, no clear subclustering of t(9;11)/MLL-AF9-positive samples was observed. Instead of being distinct from other AML with differing MLL gene rearrangements, global gene expression patterns of t(9;11)/MLL-AF9 intercalated with other AML with t(11q23)/MLL cases. This transcriptional concordance is an unexpected result. However, it would correlate with the observation of comparable clinical outcome in those subset of AML patients. 3 We failed at identifying clearly differentially expressed genes when six different MLL partner genes, that is, MLL-AF9, MLL-AF6, MLL-AF10, and MLL-ELL in AML and MLL-AF4 as well as MLL-ENL in ALL, respectively, were examined. At this step no statistically significant expression signatures were found to be specifically correlated with one of the distinct partner genes (additional data is given in the Supplementary online document). This also explains the failure of predicting the respective partner gene based on differential gene expression signatures using SVMs as classification algorithm. Given the presented data, the global gene expression profile analysis does not reveal a clear distinct pattern associated with one of the various partner genes in t(11q23)/MLL leukemias.
Further experiments are required to investigate why most of the MLL partner genes are strictly correlated with a specific leukemia subtype. Gene expression is determined not only by the available combination of transcription factors but also by the structure of the local chromatin, which is the physiological substrate for all nuclear processes including transcription and recombination. 46 Therefore, it can be speculated that at the time point of the chromosomal aberration, the hematopoietic progenitor target cell already is committed to a myeloid or lymphoid lineage development. Given the differing chromatin structure and its accessibility to regulatory factors, thus only certain genes would be suitable as fusion partner, for example, AF4 in lymphoblastic, or AF9 in myeloid leukemias. On the other hand, if the progenitor target cell is not committed to a particular lineage, the fusion partner might be able to contribute to cell-fate decisions. Then, the different MLL fusion proteins would dictate the respective differentiation pathway by facilitating the establishment of lineage-specific gene expression programs. In the gene expression patterns described here, a strong association of lymphoid commitment in ALL with t(11q23)/MLL was observed. The coexpression of PAX5, the critical B-lineage commitment factor that restricts the developmental options of early progenitors to the B-cell pathway, and early B-cell factor EBF in these samples suggests that the leukemogenic hit did occur in the earliest phase of Blymphopoiesis.
Typically, the resultant t(11q23)/MLL leukemias display features of a maturation arrest at a later stage of differentiation. This has particularly been described by Cozzio et al. 59 In this model, purified progenitor subsets, that is, hematopoietic stem cells (HSC), common myeloid progenitors (CMP), and the lineal descendent granulocytic/monocytic-restricted progenitors (GMP) were susceptible to MLL fusion protein-mediated transformation. Regardless of the initiating cell, targeted by an MLL-ENL construct, the resultant leukemias displayed immunophenotypes and gene expression profiles characteristic of maturation arrest at an identical late state of myelomonocytic differentiation downstream of the GMP.
In human leukemias, MLL-ENL occurs in both AML and ALL. Interestingly, in our cohort, myeloid and lymphoblastic gene expression profiles of MLL-ENL samples were separated. The t(11;19)(q23;p13.1) chromosomal translocation fuses the gene encoding transcriptional elongation factor ENL to the MLL gene. 60 Recent data indicate that neoplastic transformation by the MLL-ENL fusion protein is likely to result from aberrant transcriptional activation of MLL target genes. 61 This finding would further support the model of 'lineage promiscuity', a mechanism described for mixed lineage leukemias in the context of MLL-GAS7. 62 In their study, So et al had used a retroviral MLL-GAS7 construct to model acute biphenotypic leukemia (ABL) in mice. Cells that were transformed in vitro were able to induce three different leukemias in vivo, that is, AML, ALL, and ABL, which also exhibited distinct gene expression profiles for a selection of transcripts. The progenitor cells affected by the MLL oncogene were phenotypically most comparable to the multipotent progenitor (MPP), the direct progeny of short-term HSC. When injected into sublethally irradiated mice, the biphenotypic progenitors sequentially further differentiated along the myeloid or lymphoid lineages and induced AML or ALL, respectively.
In conclusion, our results underline that AML with t(11q23)/ MLL and ALL with t(11q23)/MLL are distinct entities as proposed in the current WHO classification of hematological malignancies. 63 Both subtypes share a distinct gene expression signature but on the other hand vary substantially in the expression of genes determining the lymphoid or myeloid lineage. While a clear gene expression pattern with respect to the lineage was identified, a specific signature associated with the different MLL partner genes was not observed. Microarray technology demonstrated that based on a cohort of thoroughly characterized leukemia samples, expression signatures lead to a better understanding of biological features of these specific acute leukemia subtypes. Novel networks of candidate genes were depicted and may inspire follow-up studies to elucidate the events leading to these types of prognostically unfavorable acute leukemias and may be exploited to identify new therapeutic targets.
